Alerta

SUPRAMOLECULAR IONIZABLE LIPID MOLECULES WITH HETEROATOMIC TUNING FOR NUCLEIC ACID DELIVERY

Resumen de: WO2025123134A1

The present application relates to ionizable lipids that include ester functional groups. The present application further relates to compositions and uses thereof for the delivery of agents such as nucleic acids and drugs.

Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof

Resumen de: US2025195443A1

This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that is water insoluble or poorly water soluble. The polymer is water soluble and comprises at least one first terminal group modified with H or a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. This disclosure is also directed to a method for treating or preventing a disease including one or more immune disorders, infectious diseases and cancers using the pharmaceutical composition disclosed herein. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine.

THERAPEUTIC POTENTIAL OF CURCUMIN-CYCLODEXTRIN-CELLULOSE NANOCRYSTALS IN THE TREATMENT OF PERIPHERAL NEUROPATHIES

Resumen de: EP4570261A2

L'invention concerne un complexe comprenant :- des nanocristaux de cellulose ;- au moins une molécule de β-cyclodextrine ;- au moins une molécule de curcumine,pour une utilisation dans le traitement de tout type de neuropathies périphériques. L'invention concerne également une composition pharmaceutique comprenant au moins ledit complexe et au moins un excipient pharmaceutiquement acceptable. L'invention concerne en outre l'utilisation du complexe ou de la composition pharmaceutique, sous la forme notamment d'hydrogel, d'implant sous-cutané, de pompe implantable, de conduit nerveux biofonctionnalisé implanté, pour améliorer l'observance du traitement, permettre une libération prolongée du complexe et obtenir une meilleure pharmacocinétique.

METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES

Resumen de: TW202502301A

The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. The exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.

LIPID PARTICLE

Resumen de: EP4570269A1

An object of the present invention is to provide a lipid particle that can be produced without using a PEG-modified lipid, or that exhibits higher drug effects, safety, or stability than those of a lipid particle produced using a PEG-modified lipid; or that has immunokinetics different from those of a lipid particle produced using a PEG-modified lipid.A lipid particle comprising an ionized lipid, a phospholipid, and a sterol as lipid components of the lipid particle, and a modified polysaccharide containing a hydrophobic group.

ORAL FILM WITH MODERATE NICOTINE RELEASE AND PREPARATION METHOD THEREFOR

Resumen de: EP4570237A1

The present application discloses an oral film with moderate nicotine release and a preparation method thereof. The method includes the following steps: preparing a solution of hydroxypropyl chitosan and a solution of polyanion with a nicotine salt to obtain a mixed solution, adding the mixed solution into the hydroxypropyl chitosan solution to obtain a suspension of nicotine salt nanoparticles, and centrifugally drying to obtain nicotine salt nanoparticles; preparing a film-forming solution, adding the nicotine salt and nicotine salt nanoparticles into the film-forming solution according to a compound ratio, and drying to produce a film, thus obtaining an oral film with moderate nicotine release; and the compound ratio of the nicotine salt and the nicotine salt nanoparticles is 1: (0.5-3). The preparation method of the application is straightforward, and the oral film with moderate nicotine release has good mechanical properties and good sustained release effect

NOVEL ANTIGENS FOR CANCER AND USES THEREOF

Resumen de: AU2023322307A1

Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) expressed by breast tumor cells are described herein. Synthetic long peptides, nucleic acids, compositions, cells, TCRs, antibodies and vaccines derived from these TSAs and TAAs are described. The use of the TSAs/TAAs, nucleic acids, compositions, antibodies, cells and vaccines for the prevention or treatment of breast cancer, including triple-negative breast cancer (TNBC), is also described.

POLYMER CONTRAST AGENT

Resumen de: EP4570837A1

The present invention relates to a copolymer in which a chelating agent molecule is bonded to a copolymer X comprising structural units of (A), (B), and (C).R¹, R², and R³ are the same or different and represent hydrogen or C_1-3 alkyl, R⁴ represents C_1-3 alkyl, R⁵ represents hydrogen, C_1-18 alkyl, 3- to 8- membered cycloalkyl optionally having substituent, adamantyl, C_6-18 aryl optionally having substituent, or 5- to 10- membered heteroaryl group optionally having substituent, X¹, X², and X³ are the same or different and represent oxygen, sulfur, or N-R⁷, R⁶ represents hydrogen, leaving group, or linker, R⁷ represents hydrogen or C_1-3 alkyl group, m represents 1 to 100, and n represents 0 to 3.

NOVEL COPOLYMER

Resumen de: EP4570835A1

To provide a novel copolymer utilizable for drug delivery technology.The present invention relates to a copolymer in which a target-affinity molecule is bonded to a copolymer X having structural units of (A), (B), and (C).R¹, R², and R³ are the same or different and represent hydrogen or C_1-3 alkyl; R⁴ represents C_1-3 alkyl; R⁵ represents hydrogen, C_1-18 alkyl, 3- to 8- membered cycloalkyl optionally having substituent, adamantyl, C_6-18 aryl optionally having substituent, or a 5- to 10- membered heteroaryl optionally having substituent; X¹, X², and X³ are the same or different and represent oxygen, sulfur, or N-R⁷; R⁶ represents hydrogen, leaving group, or linker; R⁷ represents hydrogen or C_1-3 alkyl; m represents 1 to 100; and n represents 0 to 3.

NEW DRUG COMPLEX

Resumen de: EP4570272A1

A novel copolymer utilizable for drug delivery technology.The present invention relates to a drug complex in which a target recognition molecule is bonded to a copolymer X comprising structural units of (A), (B), and (C) .R¹, R², and R³ are the same or different and represent hydrogen or C_1-3 alkyl, R⁴ represents C_1-3 alkyl, R⁵ represents hydrogen, C_1-18 alkyl, 3- to 8- membered cycloalkyl optionally having substituent, adamantyl, C_6-18 aryl optionally having substituent, or 5- to 10- membered heteroaryl group optionally having substituent, X¹, X², and X³ are the same or different and represent oxygen, sulfur, or N-R⁷, R⁶ represents hydrogen, leaving group, or linker, R⁷ represents hydrogen or C_1-3 alkyl group, m represents 1 to 100, and n represents 0 to 3.

METAL-PHOSPHOLIPID COMPLEX, METAL-PHOSPHOLIPID COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF

Resumen de: EP4570271A1

The present disclosure provides a metal-chelated phospholipid complex, a metal-chelated phospholipid complex nanoparticle and a drug-lipid particle, and preparation methods and uses thereof, which relates to the field of biotechnology. The metal-chelated phospholipid complex is formed by reaction of a phospholipid molecular moiety, a linker molecular moiety, and a metal ion moiety. The metal-chelated phospholipid complex nanoparticle comprises a metal-chelated phospholipid complex, a particle aggregation-inhibiting conjugated lipid, and a non-cationic lipid or a non-ionizable lipid. The drug-lipid particle comprises a drug and the metal-chelated phospholipid complex nanoparticle. The metal-chelated phospholipid complex has a function in adsorbing drugs with negative charges and self-assembling with other lipids into metal-chelated phospholipid complex nanoparticles (MPP), so as to avoid the use of cationic lipid or ionizable lipid under the condition of ensuring the effectiveness which is not less than that of LNP, so that the toxicity of the drug-lipid particle is greatly reduced compared with LNP, the biological safety is remarkably improved, and the delivery of drugs with negative charges in organisms is facilitated.

SHRINKING NANOMATERIAL FOR BIOMEDICAL APPLICATIONS

Resumen de: WO2024035784A1

A size-changing nanoparticle construct for biomedical applications, and methods to fabricate and use such nanoparticle constructs.

一种用于治疗肝细胞癌的药物及应用

Resumen de: CN120154636A

本发明公开了一种用于治疗肝细胞癌的药物及应用。本发明首先构建了硒基纳米颗粒Se/ZIF8，所述硒基纳米颗粒由Se和ZIF8组成。将该硒基纳米颗粒与NK细胞共同处理肝癌细胞，可显著增强NK细胞对肝癌细胞的杀伤活性。同时，将该硒基纳米颗粒与NK细胞共同处理原位肝癌荷瘤小鼠，可显著提升NK细胞的抑瘤效果，起到了协同增效的作用。本发明为治疗肝癌提供了新的免疫药物选择，在肝癌的临床治疗中具有广阔的应用前景。

编码水痘-带状疱疹病毒糖蛋白E的mRNA疫苗

Resumen de: CN120158462A

本申请提供了一种编码水痘‑带状疱疹(VZV)糖蛋白E(gE)或其变异体的RNA，所述RNA包含与SEQ ID NO:11‑18中任一项所示的核苷酸序列具有至少80％、至少85％、至少90％、至少95％、至少96％、至少97％、至少98％或至少99％同一性的核苷酸序列。本申请提供的八种mRNA能在细胞内翻译，产生的VZV gE蛋白表达水平高，该mRNA经由脂质体纳米颗粒包封后形成的制剂通过肌肉注射到小鼠体内的方式，可诱导小鼠产生高滴度的gE特异性IgG抗体。

一种双配体修饰的纳米递送系统

Resumen de: CN120154583A

本发明属于生物医药领域，具体涉及一种双配体修饰的纳米递送系统。本发明的主要技术方案是提供了包括包载药物的聚合物纳米粒、包裹于聚合物纳米粒表面的脂质材料，其中，脂质材料加入Aβ11和T80进行修饰。本发明公开的双配体修饰的纳米递送系统，得到的核‑壳纳米粒(Aβ11/T80@CSs‑药物)在粒径、电位、包封率数据方面优异，有利于纳米粒药物的递送；稳定性更佳，更有利于所包载的药物的运输和储藏；具有显著的穿透血脑屏障，具有显著更佳的抗菌效果；在颅内抗感染方面具有非常好的应用前景。

一类BODIPY染料及其在光热领域的应用

Resumen de: CN120157696A

一类BODIPY染料及其在光热领域的应用，其属于功能染料及生物医药的技术领域。在一般氟硼类二吡咯亚甲基染料的基础上修饰以强吸电子基团三氟甲基，经对羟基苯甲醛修饰延长共轭结构后，使其吸收波长发生了显著红移；后单侧羟基与对甲苯磺酰氯反应，得到该BODIPY染料。在经两亲性分子DSPE‑PEG2000包裹后形成纳米颗粒，结合zeta电位为负的特征，该BODIPY染料能够靶向肿瘤细胞溶酶体，然后实现溶酶体逃逸，并最终靶向内质网。这使得该BODIPY染料即使是在较温和的光热条件下进行光热治疗，也能够引起内质网应激，诱导肿瘤细胞发生免疫原性死亡，有效的杀死肿瘤细胞。本发明中BODIPY染料合成方式简单、暗毒性低、细胞杀伤效果好，具有应用于临床治疗的潜力。

一种Aβ11和T80双配体修饰的核-壳纳米粒、制备方法及其用途

Resumen de: CN120154584A

本发明属于生物医药领域，具体涉及一种Aβ11和T80双配体修饰的核‑壳纳米粒、制备方法及其用途。本发明的主要技术方案是提供了包括包载药物的聚合物纳米粒核、包裹于聚合物纳米粒核表面的脂质材料，脂质材料加入Aβ11和T80进行修饰。本发明公开的双配体修饰的核‑壳纳米粒，在粒径、电位、包封率数据方面优异，有利于纳米粒药物的递送；稳定性更佳，更有利于所包载的药物的运输和储藏；具有显著的穿透血脑屏障，具有显著更佳的抗菌效果；药代动力和药效动力以及安全方面效果显著，在颅内抗感染方面具有非常好的应用前景。

신규 이온화 가능한 지질

Resumen de: AU2023361218A1

The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.

Anticancer composition containing gold-nanorods combined with glucuronic acid

Resumen de: KR20250086122A

본 발명은 글루쿠론산 결합 금나노로드 및 이를 포함하는 항암용 조성물에 관한 것으로서, 상기 금나노로드는 암세포 선택적으로 세포 내 이온 불균형을 일으키고, Caspase-3/7 활성화, 아폽토시스, 활성산소 발생을 유도함으로써 암세포의 세포막 변형을 일으켜 암치료에 효과적임을 제시한다.

DNA Prussian blue nano particles coated with Salmon-derived DNA and use thereof

Resumen de: KR20250085875A

본 발명은 연어유래 DNA 코팅 프러시안 블루 나노입자 및 이의 용도에 관한 것이다. 보다 구체적으로, 본 발명은 연어유래 DNA로 코팅된 프러시안 블루 나노입자 및 이의 용도, 예를 들면 항산화제, 항염증제, 약제학적 조성물, 의약외품 조성물, 화장료 조성물 또는 식품 조성물에서의 용도에 관한 것이다.

靶向细胞核的基因编辑递送载体、纳米颗粒以及制备方法和应用

Resumen de: CN120131974A

本发明涉及一种基因编辑递送载体、递送系统及其制备方法和应用。该载体为利用苯硼酸对线性聚乙烯亚胺改性制得获得的细胞核靶向高分子载体。利用该载体制备的纳米颗粒和纳米递送系统，无需进行额外的传统核定位序列(NLS)肽修饰，即可具有超高的细胞核靶向能力，能够在活细胞及体内水平进行高效的基因编辑，并在细胞核区域对目的基因进行实时成像，显著提高了活细胞和体内基因编辑的效率和核酸检测的准确性。同时具有易于制备、基因编辑效率高、检测灵敏度高等优点。

一种具有抗菌和成像功能的钛酸钡/铋@聚吡咯纳米材料及其制备方法和应用

Resumen de: CN120132005A

本发明提供了一种具有抗菌和成像功能的钛酸钡/铋@聚吡咯纳米材料及其制备方法和应用。包括：S1.用水热法制备钛酸钡；S2.在钛酸钡纳米颗粒表面负载铋单质，构建钛酸钡/铋异质结；S3.在冰水浴下，将钛酸钡/铋异质结与预氧化的吡咯单体复合，制成钛酸钡/铋@聚吡咯纳米材料。本发明制备的钛酸钡/铋@聚吡咯纳米材料具有良好的生物相容性，优异的抗菌和成像性能，可用于创面或骨缺损修复等领域，可实现非侵入性、高效性和可控性抗菌，并可用于实时监测。

一种新型纳米颗粒递药系统的制备方法及应用

Resumen de: CN120131585A

本发明涉及医药技术领域，尤其涉及一种新型纳米颗粒递药系统的制备方法及应用；包括以下步骤：A、将活化后的牛血清白蛋白加入到孔板中，再加入2‑吗啉乙磺酸缓冲溶液，在振荡条件下加入异槲皮苷溶液反应，反应后经洗涤得到BSA@ISO；B、将RVG29多肽溶在PBS中，加入步骤A中BSA@ISO溶液，搅拌反应后，经透析、离心得到BSA@ISO‑RVG29；C、向Ti2C中加入1‑(3‑二甲氨基丙基)‑3‑乙基碳二亚胺盐酸盐，接着加入N‑羟基琥珀酰亚胺，反应后加入步骤B中的BSA@ISO‑RVG29反应，反应后经洗涤得到Ti2C‑BSA@ISO‑RVG29。在牛血清白蛋白包裹疏水药物异槲皮苷(ISO)，并接枝RVG29靶向肽，之后装载在具有强自由基清除能力的Ti2C纳米酶上，成功制备了用于缺血性卒中治疗的纳米制剂。

一种硒基抗绝经后骨质疏松药物及其制备方法和应用

Resumen de: CN120131919A

本发明涉及医用制剂技术领域，具体公开了一种硒基抗绝经后骨质疏松药物及其制备方法和应用，包括：主活性成分，为纳米硒‑植物雌激素复合物，由硒代蛋氨酸与大豆异黄酮通过共价偶联形成，其粒径为50‑200nm，硒元素质量占比为复合物的5％‑30％；辅助活性成分，为胶原肽‑钙螯合物，由海洋胶原肽与柠檬酸钙通过螯合反应制备，钙元素与胶原肽的质量比为1:3‑1:5；靶向递送载体，为叶酸修饰的壳聚糖纳米粒，负载所述主活性成分与辅助活性成分；辅料，包括崩解剂、润滑剂及pH敏感型肠溶包衣材料；本发明通过主活性成分纳米硒‑植物雌激素复合物与辅助活性成分胶原肽‑钙螯合物的协同作用，能够同时促进骨形成与抑制骨吸收，实现了双功能治疗。

一种光磁可视化生物杂化纳米体系及其制备方法和应用

Nº publicación: CN120131586A 13/06/2025

Solicitante:

中国医学科学院生物医学工程研究所

Resumen de: CN120131586A

本发明公开了一种光磁可视化生物杂化纳米体系及其制备方法和应用，所述光磁可视化生物杂化纳米体系包括血小板膜以及包裹在所述血小板膜内的负载氯沙坦的单宁酸锰络合物；本发明光磁可视化生物杂化纳米体系能够促进药物和免疫细胞的深层渗透性，并利用血小板膜的生物趋向性实现肿瘤靶向治疗，此外，还能够通过荧光成像和磁成像双重成像模式为精准靶向治疗提供可视化跟踪。